Jefferies Group’s Myriad Genetics MYGN Stock Holding History

Jefferies Group’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-17,500	Closed	-$486K	–	2914
2019 Q2	$486K	Sell	17,500 -22,500	-56%	-$635K	﹤0.01%	1684
2019 Q1	$1.33M	Buy	+40,000	New	+$1.22M	0.01%	1121
2016 Q1	–	Sell	-10,000	Closed	-$432K	–	2452
2015 Q4	$432K	Hold	10,000	–	–	﹤0.01%	1606
2015 Q3	$375K	Hold	10,000	–	–	﹤0.01%	1646
2015 Q2	$340K	Sell	10,000 -164,500	-94%	-$5.59M	﹤0.01%	1732
2015 Q1	$6.18M	Buy	174,500 +143,300	+459%	+$5.13M	0.03%	361
2014 Q4	$1.06M	Hold	31,200	–	–	0.01%	951
2014 Q3	$1.2M	Sell	31,200 -16,200	-34%	-$604K	0.01%	940
2014 Q2	$1.84M	Buy	47,400 +21,200	+81%	+$789K	0.02%	665
2014 Q1	$896K	Buy	+26,200	New	+$812K	0.01%	978
2013 Q3	–	Sell	-110,000	Closed	-$2.96M	–	2097
2013 Q2	$2.96M	Buy	+110,000	New	+$3.19M	0.03%	365

Other funds holding MYGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GCM

Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's MYGN Position: Q2 2019 in Review

Jefferies Group sold out of Myriad Genetics (MYGN) in Q2 2019, closing a stake of 85,131 shares — an estimated $2.4M sold.

Jefferies Group first reported a position in MYGN in Q2 2013 and held it in 12 quarters. The position peaked at $2.83M in Q1 2019. 235 funds tracked by Wall St. Rank hold MYGN as of Q2 2019.

Jefferies Group reported no remaining Myriad Genetics position as of Q2 2019 after selling out during the quarter.
Jefferies Group sold 85,131 Myriad Genetics shares in Q2 2019, an estimated $2.4M.
Jefferies Group first reported a position in Myriad Genetics in Q2 2013 and held it in 12 quarters.
Jefferies Group's Myriad Genetics position peaked at $2.83M in Q1 2019.
235 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2019.

Based on Jefferies Group's 13F filing for Q2 2019, filed 14 Aug 2019.